News & Events about Inhibrx Inc.
Inhibrx, Inc. (NASDAQ:INBX Get Rating) insider Brendan P. Eckelman sold 28,750 shares of the businesss stock in a transaction dated Wednesday, February 1st. The shares were sold at an average price of $24.73, for a total value of $710,987.50. Following the completion of the sale, the ...
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of the firms stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the sale, the chief executive officer now ...
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of Inhibrx stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the transaction, the chief ...
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates PR...
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma PR...